Default company panoramic image
Fcaf00b6 8028 49f0 9bf0 3899b47dfda6

DeNovo Sciences

Our mission is to develop and sell integrated platforms that accelerate cancer discoveries and the early detection of metastasis.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Plymouth, MI, USA
  • Currency USD
  • Employees 4
  • Website

Company Summary

DeNovo Sciences is committed to the development and sale of an integrated platform that improves cancer research, diagnosis and treatment by capturing rare circulating tumor cells from a simple blood-draw. This technology will allow patients to avoid undergoing painful biopsies, and provide clinicians with important information regarding the selection of treatment courses and patient prognosis.


  • Default avatar
    Kalyan Handique, Ph.D.
    Chief Executive Officer

    Co-founder, CTO & Board Member of Handyab (acquired by BD for $275MM); 11+ years commercialization experience in microfluidics, molecular diagnostics and IVD; VP at BD diagnostics (2009-11).

  • Default avatar
    Roger Newton, Ph.D.
    Business Adviser

    Currently the Founder, President and CEO of Esperion Therapeutics; 27+ years pharmaceutical and life science experience; Founder of Esperion I (acquired by Pfizer for $1.3 Billion); Co-discovered (Lipitor®) while a distinguished scientist at Warner Lambert/Parke-Davis (now Pfizer)

  • Default avatar
    Mark Powelson, MBA
    Business Adviser (Management in waiting--Sales and Marketing)

    25 years of sales and marketing for HandyLab, Boehringer Manheim/Roche Diagnostics, Chiron Diagnostics, and Eli Lily

  • Default avatar
    Steve Richvalsky
    Business Adviser (Management in waiting--CFO)

    25 years of CFO for BD Ann Arbor, HandyLab, Genomic Solutions and Ardesta

  • Default avatar
    Ramzi Mohammad, Ph.D.
    Scientific Adviser/Collaborator

    Director, Oncology, Karmanos Cancer Institute, 30 years in cancer research